U.S. Disinfecting Cap Market to Surpass US$ 810.3 Million by 2027. Get the latest updates on 'U.S. Disinfecting Cap Market' here.

tannertan36
Xuebing Du

祝日 / Permanent Vacation

Love Begins
let's talk about Bridgerton tea, my ask is open
noise dept.
hello vonnie

PR's Tumblrdome
One Nice Bug Per Day
Sweet Seals For You, Always
trying on a metaphor

roma★
PUT YOUR BEARD IN MY MOUTH
Aqua Utopia|海の底で記憶を紡ぐ
Cosimo Galluzzi
wallacepolsom
we're not kids anymore.
Not today Justin

Origami Around
🪼

seen from United States
seen from United States
seen from United States
seen from Brazil
seen from United States

seen from Malaysia
seen from Philippines

seen from Germany
seen from United States

seen from United States

seen from Bulgaria

seen from United States

seen from Türkiye
seen from United States
seen from United States
seen from United States

seen from France
seen from Canada

seen from South Korea
seen from United States
@sriramnanda-blog
U.S. Disinfecting Cap Market to Surpass US$ 810.3 Million by 2027. Get the latest updates on 'U.S. Disinfecting Cap Market' here.
Disposable Incontinence Products Market is expected to reach US$ 13,939.9 Mn by the end of 2027.
Bacterial Filter Market to Surpass US$ 3,526.1 Million by 2027. Get the latest updates on the 'Bacterial Filter Market' here.
Get the latest updates on 'Disposable Incontinence Products Market' here.
Europe Cryochambers Market to Surpass US$ 76.5 Million by 2027. Get the latest updates on 'Europe Cryochambers Market' here.
Dysphagia Management Market to Surpass US$ 5,040.7 Million by 2027. Get the latest updates on 'Dysphagia Management Market' here.
Get the latest updates on 'Diabetic Gastroparesis Treatment Market' here.
Get the latest updates on 'Inactivated Polio and Rabies Vaccines Market' here.
PRIMARY BILIARY CHOLANGITIS TREATMENT MARKET ANALYSIS
Primary biliary cirrhosis, also known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis include itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat, and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and may cause the liver to stop working completely in later stages.
The global primary biliary cholangitis treatment market size was valued at US$ 526.4 million in 2017, and is expected to witness a CAGR of 36.3% during the forecast period (2018 – 2026).
Figure 1. Global Primary Biliary Cholangitis Treatment Market Value Analysis (US$ Mn) and Forecast and Absolute $ Opportunity
Source: Coherent Market Insights Analysis (2019)
Increasing number of pipeline studies is expected to drive the primary biliary cholangitis treatment market growth
Increasing pipeline studies to develop prominent treatments for rare diseases such as primary biliary cholangitis are expected to boost the primary biliary cholangitis treatment market size. For instance, in October 2018, CymaBay Therapeutics, Inc., initiated placebo-controlled and randomized phase 3 clinical trial for seladelpar 5-10mg. The aim of the study was to evaluate safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) and to determine inadequate response or intolerance to ursodeoxycholic acid (UDCA). The study is estimated to complete in December 2021.
Moreover, in January 2017, GlaxoSmithKline (GSK) initiated phase 2 clinical trial to study the efficacy, safety, and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). GSK2330672 is a selective inhibitor of human ileal bile acid transporter (IBAT). The study is estimated to complete in April 2020.
Primary Biliary Cholangitis Treatment Market- Regional Analysis
Regional segmentation of the global primary biliary cholangitis treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is anticipated to witness lucrative primary biliary cholangitis treatment market growth, owing to growing initiatives by market players to develop advance treatment options for PBC. For instance, in October 2016, TARGET PharmaSolutions, Inc., U.S.-based Company, in collaboration with Intercept Pharmaceuticals, Inc., launched its TARGET-PBC (Primary Biliary Cholangitis) platform. TARGET-PBC platform has been created to improve the understanding of real world treatment patterns in PBC.
Asia Pacific is also expected to witness significant growth in the primary biliary cholangitis treatment market. For instance, in 2017, the Japanese Biliary Association (JBA) and the Intractable Hepatobiliary Disease Study Group of Japan estimated that there were 2,000 to 3,000 patients with PBC in Japan. Also, in 2017, Japanese researchers planned to collect DNAs from Japanese PSC patients, to examine difference in genetic background between the East and the West of Japan.
Europe is expected to witness significant market share in the market, owing to rising initiative by professional organizations to create awareness among the healthcare professionals to treat the patients suffering from rare diseases such as primary biliary cholangitis. For instance, April 2018, the British Society of Gastroenterology and UK-PBC entered into strategic partnership to develop a comprehensive guidelines for the treatment of primary biliary cholangitis. The guidelines are mainly designed for gastroenterologists and herpetologists engaged in providing treatment to the patients with PBC.
Figure 2: Global Primary Biliary Cholangitis Treatment Market Value (US$ Mn), By Region, 2017
Source: Coherent Market Insights Analysis (2019)
Primary Biliary Cholangitis Treatment Market - Competitive Landscape
Key players operating in the primary biliary cholangitis treatment market include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, Retrophin, Inc., Calliditas Therapeutics AB., and GlaxoSmithKline (GSK) pharmaceutical.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]
ANESTHESIA DEVICE MARKET ANALYSIS
Anesthesia devices includes monitors, continuous-flow anesthetic machines, anesthetics vaporizers, anesthesia information management system (AIMS), and other disposables such as anesthesia breathing circuits, endotracheal tubes, anesthesia gas masks, and laryngeal mask airway. Anesthesia machines are used to administer anesthesia in patients during surgery. These machines deliver variable gas mixtures, which are then delivered to the breathing systems for administering gases to patients using oxygen mask. Patients are administered a mixture of oxygen, nitrous oxide, and other gases that are regulated by anesthetic machines.
The global anesthesia device market size was valued at US$ 10,571.6 million in 2017, and is expected to witness a CAGR of 7.3% during the forecast period (2018 – 2026).
Figure 1. Global Anesthesia Device Market Value Analysis (US$ Mn) and Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2019)
Increasing number of surgical procedures is expected to drive growth of the anesthesia device market
Increasing number of surgical procedures that lead to high demand for anesthesia devices is one of the major drivers for the market growth. For instance, according to Healthcare Cost and Utilization Project, in 2014, around 17.2 million patients visited hospital (ambulatory or inpatient) for invasive and therapeutic surgeries. Of which, 57.8% of surgeries occurred in a hospital-owned ambulatory surgery (AS) setting and 42.2% of surgeries were performed in hospital inpatient settings in U.S..
Moreover, manufacturers are engaged in developing technologically-advanced medical devices, which in turn is contributing to the anesthesia devices market growth. For instance, in January 2019, Mindray Medical International Ltd. launched A-Series Advantage Anesthesia Delivery platform, which is a modular, state-of-the-art family of anesthesia solutions that includes A4, A5, and A7 Advantage systems.
Anesthesia Device Market- Regional Analysis
Regional segmentation of the global anesthesia device market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America anesthesia device market is expected to account for the largest market share, owing to presence of large number of ambulatory surgical centers (ASCs) and hospital inpatient settings in this region. For instance, in 2017, according to Becker’s ASC Review, there were 5,480 Medicare-certified ASCs and 5,564 registered hospitals in the U.S.
Moreover, manufacturers and healthcare organization in this region are focused on spreading awareness among healthcare providers and surgeons about anesthesia devices used in various surgical procedures. For instance, in May 2018, the American Society of Anesthesiologists (ASA) and CAE Healthcare launched interactive, screen-based simulation training product line Anesthesia SimSTAT. Anesthesia SimSTAT – Appendectomy training is designed to offer physician anesthesiologists to manage challenging anesthetic emergencies in patients undergoing laparoscopic surgeries for acute appendicitis.
Presence of major player such as Medtronic plc, Getinge AB, and Draegerwerk AG & Co. KGaA in European countries is expected to drive growth of the Europe anesthesia device market. For instance, in November 2012, Covidien -- minimally invasive therapies division of Medtronic plc. — announced that UK-based National Institute for Health and Clinical Excellence (NICE) has approved the use of its electroencephalography (EEG)-based monitor — Bispectral Index (BIS) monitor— as an option for measuring depth of anesthesia.
Figure 2: Global Anesthesia Device Market Value (US$ Mn), By Region
Source: Coherent Market Insights Analysis (2019)
Anesthesia Device Market - Competitive Landscape
Key players operating in the anesthesia device market include, GE Healthcare, Spacelabs Healthcare., Septodont Inc, Draegerwerk AG & Co. KGaA, Beijing Aeonmed Co., Ltd., HEYER Medical AG, ORICARE, Inc., Philips Healthcare, Becton Dickinson and Company, and Getinge AB.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]
IMMUNE CHECKPOINT INHIBITORS MARKET ANALYSIS
Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.
Introduction of novel immune checkpoint inhibitors with less side effects is driving global immune checkpoint inhibitors market growth
Cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to better understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Immune checkpoint inhibitors exhibit lesser side effects as compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Manufactures are developing immune checkpoint inhibitors, which are tailored to attack or block particular targets. For instance, Iplimumab, a human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Moreover, in April 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC), who are not eligible for cisplatin chemotherapy, which is currently in the clinical phase 4.
The global immune checkpoint inhibitors market size was valued at US$ 10,543.8 million in 2017, and is expected to witness a robust CAGR of 11.8% over the forecast period (2018 – 2026).
Figure No.1: Global Immune Checkpoint Inhibitors Market Share (%), by Region, 2018 and 2026
Source: Coherent Market Insights Analysis (2017)
Active research and development by leading players as well as small innovative organizations are expected to boost growth of the immune checkpoint inhibitors market
Immune checkpoint inhibitor is gaining significant traction as an efficient therapy for cancer treatment worldwide owing to less side effects, and targeted therapeutic effect. Therefore, various pharmaceuticals, biotech companies, universities, and cancer centers are focusing on investing in this segment. According to the Tufts Center for the Study of Drug Development (CSDD) report, 2016, currently, over 130 biotech and 20 pharma companies are developing immuno-oncology therapies, thereby fueling immune checkpoint inhibitors market growth in the forecast period. Also, according to the New York-based, Cancer Research Institute (CRI), 2017, currently 2,004 immuno-oncology agents including 940 in clinical stage and 1,064 in preclinical stage are under development. Leading players are actively investing in research and development in oncology treatment through various collaborations and individual research studies, owing to benefits associated with immune-oncology therapies. Advent of innovative immune-oncology therapies such as immune checkpoint inhibitors, have supported growth of the market. For instance, in 2016, AbbVie and the University of Texas MD Anderson Cancer Center entered into a three-year agreement for focusing on immune system’s complete potential to fight against cancer.
Figure No.2: Global Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis and Forecast and Y-o-Y Growth (%) (2018-2026)
Source: Coherent Market Insights Analysis (2017)
Table No.1: Atezolizumab (Tecentriq) Years of Approval and Indications
Year of ApprovalAtezolizumab (Tecentriq) Indication
2016Urothelial Carcinoma
2016Specific Type of Metastatic Lung Cancer
2017Initial Treatment for Certain People with Advanced Bladder Cancer
2018Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
2019Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast.
However, high cost of immuno-oncology therapies, which is unaffordable to low and middle income population is restraining immune checkpoint inhibitors market growth. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer cost around US$ 2,250 for a vial of 50 mg.
Some of the major players operating in the immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]
ENDOTRACHEAL TUBE MARKET ANALYSIS
Trachea, commonly known as windpipe, is a tube that connects the larynx to the bronchi of the lungs. Trachea serves as a passageway for air from the upper respiratory tract (throat and larynx) to the bronchi. Endotracheal tubes are hollow and flexible plastic tubes, which are placed from mouth to the trachea, when a person is not able to breathe on his own. The endotracheal tubes are connected to the ventilator that provides sufficient oxygen to the patient. The process of inserting endotracheal tube is known as endotracheal intubation (EI). Endotracheal tubes are available in different types such as cuffed, uncuffed, and reinforced.
A cuffed endotracheal tube is surrounded by an inflatable cuff, which is used to provide an airway through the trachea and at the same time prevent aspiration of foreign materials such as saliva or vomitus into the bronchus. An uncuffed endotracheal tube is a flexible plastic tube that is placed through the mouth into the trachea to help the patient breathe. The endotracheal tube is connected to a ventilator, which delivers oxygen to the lungs. Reinforced or armored endotracheal tubes are flexible and resistant to blockage. The flexibility is achieved with the help of a spiral of wire embedded into the wall of the endotracheal tube to give it strength and flexibility at the same time. There are other types of endotracheal tubes such as laser resistant endotracheal tubes, double lumen tubes, bronchial blocker, and microlaryngeal tubes.
The global endotracheal tube market is expected to be valued at US$ 739.4 million in 2019, and is expected to exhibit a CAGR of 6.4% over the forecast period (2019-2027).
Figure 1. Global Endotracheal Tube Market Value (US$ Mn), by Region, 2019
Source: Coherent Market Insights Analysis (2020)
Increasing product approvals and launches are expected to propel the market growth over the forecast period
Key players are focused on enhancing their product portfolio through increasing launches and approvals of advanced and efficient endotracheal tubes, which is expected to drive growth of the endotracheal tube market over the forecast period. For instance, in November 2016, Bactiguard launched its new BIP Endotracheal Tube Evac to prevent patients from ventilator associated pneumonia (VAP). The novel BIP Endotracheal Tube Evac features both subglottic secretion drainage and a Bactiguard coating to prevent ventilator associated pneumonia (VAP) infections.
Figure 2. Global Endotracheal Tube Market Share (%), by Route, 2027
Source: Coherent Market Insights Analysis (2020)
Increasing technological advancements in endotracheal tubes is expected to drive the market growth over the forecast period
Manufacturers are focusing on development of innovative endotracheal tubes in order to prevent the hospital acquired infections. For instance, In February, N8 Medical, LLC submitted the Investigational Device Exemption (IDE) to the Food and Drug Administration (FDA) for the first-in-human clinical study of its CeraShield Endotracheal Tube (ETT). The objective of the clinical study is to evaluate the safety and efficacy of the CeraShield Endotracheal Tube (ETT).
However, increasing prevalence of hospital acquired infections such as ventilator associated pneumonia is expected to hinder the endotracheal tube market growth over the forecast period. For instance, according to the National Center for Biotechnology Information, in November 2017, each year in the U.S. ventilator-associated pneumonia (VAP) incidence range from 2 to 16 episodes per 1,000 ventilator-days.
Key Players
Major players operating in the global endotracheal tube market include Medtronic Plc, Teleflex Inc., ConvaTec Inc., Smiths Medical, Neurovision Medical Products, Intersurgical Inc., Royax, Novo Klinik-Service GmbH, Avanos Medical, Inc., Bactiguard, and N8 Medical LLC.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]
PROGRAMMABLE INFUSION PUMPS & CATHETERS MARKET ANALYSIS
Programmable infusion pumps and catheters are devices used for delivering fluids to the patient’s body in a controlled manner. The devices include safety features such as user alerts which are activated when there is a risk of adverse drug interaction, or when the pump’s parameters are set outside its specified safety limits. Infusion pumps are used for different purposes such as delivering nutrients or medications like antibiotics, chemotherapeutic drugs, analgesics, hormones such as insulin, and so on. These are generally designed for stationary use, that is along patient’s bedside in an ICU setting, however few such as the ambulatory infusion pumps, are portable. Infusion pumps are designed for specific purposes. For instance, the enteral pump is designed to deliver medication to patient’s digestive tract through tube feeding.
Increasing launch of novel infusion pumps is expected to boost the global programmable infusion pumps and catheters market growth over the forecast period
Frequent approvals of novel infusion pumps and their launches in developed economies are expected to significantly drive the global programmable infusion pumps and catheters market growth over the forecast period. For instance, in April 2018, Smiths Group plc. launched its new product, CADD-Solis wireless infusion pump, for safe delivery of analgesics. These infusion pumps are portable and have wireless software and drug library updation facility without the need to find, plug in and update the pump personally.
In April 2013, Flowonix Medical Inc., a medical device company involved in the manufacture of implantable drug delivery systems, launched the Prometra programmable intrathecal pump in the U.S. The pump is implantable and effective in delivering Infumorp (preservative free morphine) in patients undergoing treatment for chronic pain as it directly delivers the medication in the intrathecal space around the spinal cord. The Prometra pump uses a dual-gated valve drug delivery mechanism for accurate dosing.
The global programmable infusion pumps and catheters market was valued at US$ 8,365.3 million in 2017, and is expected to witness a robust CAGR of 5.8% over the forecast period (2018–2026).
Figure No.1: Global Programmable Infusion Pumps and Catheters Market Share, By Region (%), 2018 - 2026
Source: Coherent Market Insights Analysis (2017)
Company strategies such as acquiring funding for research and product launches, are expected to have a positive impact on global programmable infusion pumps and catheters market growth.
Key players are involved in research and development of new products, which is expected to aid in growth of the market. For instance, in March 2017, Ivenix, Inc., a medical technology company involved in development of next generation infusion systems, raised US$ 50 million. Funds were raised via equity financing led by new undisclosed investors and by participation of existing investors, WuXi Healthcare Ventures and F-Prime Capital Partners, which will be used for pursuing the FDA clearance and commercial launch of products.
Novel programmable infusion pumps have been granted approval by regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Commission (EC), Therapeutic Goods Administration (TGA), and others. For instance, in August 2018, Baxter International Inc. received CE approval for its Evo IQ Infusion System, a programmable volumetric infusion pump, and marketing approval from the Therapeutic Goods Administration (TGA) in Australia. The Evo IQ Infusion System consists of a software for dose error reduction and an advanced drug library to promote patient safety. Such product launches are expected to boost the global programmable infusion pumps and catheters market growth during the forecast period.
Figure No.2: Global Programmable Infusion Pumps and Catheters Market Size (US$ Mn) Analysis and Forecast and Y-o-Y Growth (%)
However, high costs of programmable infusion pumps and catheters is a major concern (in regions with underdeveloped reimbursement facilities) in the healthcare system, and is expected to restrain the global programmable infusion pumps and catheters market growth over the forecast period.
Furthermore, efficient technicians are needed for monitoring of infusion parameters available in the programmable device. These factors are expected to restrain the global programmable infusion pumps and catheters market growth over the forecast period.
Some of the major players operating in the global programmable infusion pumps and catheters market include, ICU Medical, Inc., Smiths Group plc., Baxter International Inc., Fresenius Se & Co. KGaA, Johnson & Johnson, Medtronic plc., Becton, Dickinson and Company, Terumo Corporation, B. Braun Melsungen AG, and Moog Inc.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]
U.S. NON-ONCOLOGY BIOPHARMACEUTICALS MARKET ANALYSIS
Biologics can be defined as molecules derived from living cells such as microorganisms, plants or animal cells and used in the treatment, diagnosis or prevention of diseases. Most of the biologic molecules are very large, complex molecules or mixture of molecules.
Biopharmaceuticals are part of a wider category of therapeutic agents called biologics. Biopharmaceuticals are the substances developed in living systems with the help of biotechnology and are used in therapeutic and diagnostic applications. Non-oncology biopharmaceuticals are the drugs that are used in the treatment of various diseases rather than cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.
Increasing launches, approvals, and robust pipeline of novel biopharmaceuticals for non-oncology indications .
Frequent approvals, launches, and robust pipeline of novel non-oncology biopharmaceuticals for various indications in the U.S. market is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth.
For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection, for the preventive treatment of migraine in adults.
In February 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) approved a label update for its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis.
In July 2018, Amgen Inc. and UCB Inc. resubmitted the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
The U.S. non-oncology biopharmaceuticals market size was valued at US$ 116.0 Bn in 2018 and is expected to witness a CAGR of 10.2% during the forecast period (2018 – 2026).
Figure 1. U.S. Non-oncology Biopharmaceuticals Market Share (%), By Product Type, 2018-2026
Source: Coherent Market Insights Analysis (2018)
Increasing mergers and collaborations among key players for development of novel non-oncology biopharmaceuticals is expected to support the market growth
Key players in the market are involved in strategic mergers and collaborations for the development of new biopharmaceutical products and to market them in the U.S. Such strategic mergers and collaborations between key players is expected to support the development of novel products, which in turn is expected to fuel the U.S. non-oncology biopharmaceuticals market growth over the forecast period.
For instance, in 2017, Sanofi S.A. and its vaccines business unit Sanofi Pasteur collaborated with MedImmune, the global biologics research and development arm of AstraZeneca Plc., for the development and commercialization of a monoclonal antibody, namely MEDI8897, for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.
High price of branded biologic products is expected to be a major factor negatively affecting its adoption
According to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira comes with a list price of US$ 38,000, and according to the report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.
Table 1. Revenue of Top Non-oncology Biopharmaceutical Brands in the U.S.
Source: Coherent Market Insights Analysis (2018)
Market Opportunity
In the recent past, various blockbuster biologics such as Humira and Remicade lost patent in the U.S. market. Furthermore, various other high revenue generating biologics are expected to lose their patents in the near future.
Loss of patent in the U.S. market offers lucrative opportunity to other players for development of its biosimilars. Hence, key players in the market are focused on launch and development of biosimilars of biologic products in the market at affordable price.
For instance, in 2017, Merck & Co., Inc. launched RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab) by Janssen Biotech, Inc. As per the company, RENFLEXIS is introduced in the U.S. at a list price (wholesaler acquisition cost) of US$ 753.39, representing a 35% discount to the current list price of Remicade, which is its reference product.
Market Challenges
High R&D Investments: Developing an IV/injectable biopharmaceutical requires sophisticated infrastructure, skilled scientists, and significant resource investment. Development of a biopharmaceutical product requires extensive clinical research and multiple phases of trials, which is a lengthy and expensive process. These factors are significant barriers for the new players to enter the market.
Sales and Marketing: The U.S. non-oncology biopharmaceuticals market has established market players with strong sales and marketing team. Presence of such strong players in the country creates a big challenge for new players to enter the market and to sustain against such big players.
Physician Acceptance: Physician acceptance of substitutes for well-established products may be a challenge, particularly among indications for which numerous products are available and substitutes do not exhibit high/ better safety profile and/or lower cost.
Key players operating in the U.S. non-oncology biopharmaceuticals market include Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]
CORDYCEPS SINENSIS & MILITARIS EXTRACT MARKET ANALYSIS
Cordyceps Sinensis and C. militaris is a combination of parasitic fungus species and dead caterpillars that offer several potential health applications. It has been used in Traditional Chinese medicine, and Tibetan medicine as a remedy for around 21 ailments such as low immunity, high blood pressure etc. Cordyceps spores grow inside the caterpillar’s body and infect it, thus slowly degrading the living larva and mummify it in the soil. A cordyceps stem eventually emerges from head part of the caterpillar.
Major active ingredients in cordyceps sinensis extract include cordycepin, adenosine, exopolysaccharide fraction (EPSF), cordyglucans, and monosaccharide saponin. Scientific studies and clinical trials have found that cordyceps sinensis extract can aid treatment of diabetes, high cholesterol, and hypertension. Furthermore, it boosts immunity and acts as a stress reliever in stress related disorders.
The global cordyceps sinensis and militaris extract market size was valued at US$ 473.4 million in 2018, and is expected to witness a CAGR of 10.4% during the forecast period (2018 – 2026).
Figure 1. Global Cordyceps Sinensis and Militaris Extract Market value Analysis (US$ Mn) and Forecast and Absolute $ Opportunity
Source: Coherent Market Insights Analysis (2019)
Increasing emergence of traditional Chinese medicine in medicinal community is expected to drive growth of the cordyceps sinensis and militaris extract market
Traditional Chinese medicine (TCM) Cordyceps sinensis and C. Militaris are the potential bio-metabolites for herbal medicines. This cordyceps category has shown considerable significance in several clinical and biotechnological applications such as genetic and nutritional requirements.
TCM comprises traditional Chinese medicinal materials, decoction pieces, Chinese patented medicines, herbal extracts, and healthcare products. Internationalization of TCM products is expected to help other countries and regions to develop and produce traditional Chinese medicines in order to serve the healthcare industry. Among all the TCM products, Cordyceps sinensis is the most explored species, followed by C. millitaris.
For instance, as per the National Center for Biotechnology Information report, in 2016, the total import and export value of TCM was accounted for US$ 4.6 Bn, which represented 4.45% of the total value of import and export of Chinese pharmaceutical products. However, the value of export declined by 9.13%, from US$ 3.77 Bn in 2015 to US$ 3.426 Bn in 2016, while the import value increased by 14.50%, from US$ 1.025 Bn in 2015 to US$ 1.174 Bn in 2016.
High cost of cordyceps sinensis is a major factor that hinders the market growth. In emerging economies such as Africa and Latin America, adoption of such expensive traditional Chinese medicine is low.
Wild cordyceps sinensis is not used in most of the cordyceps supplements due to its high price. In 2016, according to BBC estimation, the cost of wild cordyceps sinensis was over US$ 20,000 per kilogram.
Cordyceps Sinensis and Militaris Extract Market- Regional Analysis
Regional segmentation of the global Cordyceps Sinensis and Militaris Extract Market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Manufacturers in North America region are importing cordyceps sinensis extract to produce different types of medical formulations such as tablets and capsules. For instance, in August 2018, HANAH Life, the developer of Ayurvedic super food HANAH ONE, launched its Cordyceps+ in the North America market. Cordyceps+ is a combination of wild Bhutanese Cordyceps sinensis, with eight other herbs and minerals. The price of HANAH Cordyceps+ is US$168 for 30 capsules in the U.S. Furthermore, increasing number of patients with mental disorders is expected to significantly expand adoption of cordyceps sinensis extracts as it has immense benefits in lowering symptoms related to mental disorders such as depression, anxeity.
Asia Pacific is expected to exhibit significant growth in the cordyceps sinensis and militaris extract extract market, owing to increasing production of cordyceps sinensis and militaris extract in this region. Cordyceps species including C. sinensis and C. militaris are mainly found at province with high altitude high altitude such as Tibet, and Chinese provinces of Sichuan, Yunnan, Qinghai and Gansu which is contributing to growth of this market in this region. For instance, according to data presented by the Ministry of Agriculture and Rural Affairs of the People’s Republic of China in 2011, China has 200,000 kg of Cordyceps, out of which 120,000 kg was harvested.
Figure 2: Global Cordyceps Sinensis and Militaris Extract Market Value (US$ Mn), By Region
Source: Coherent Market Insights Analysis (2019)
Cordyceps Sinensis and Militaris Extract Market - Competitive Landscape
Key players operating in the cordyceps sinensis and militaris extract market include Naturalin bio-resources co., Ltd, The Lubrizol Corporation, Quyuan sunnycare Inc., Shanghai Kangzhou Fungi Extract Co., Ltd., Xi'an Saina Biological Technology Co., Ltd. (Herbsino), Dalong Biotechnology Co., Ltd, Health Choice Limited, Nutrastar International Inc., Nutra Green Biotechnology Co., Ltd.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]
INFERTILITY DEVICES MARKET ANALYSIS
Infertility patients are opting for various type of treatments such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and other procedures. IVF is the most common technique to treat infertility. The adoption and success rate of IVF is high. For instance, according to a clinical study conducted by IVF Australia in 2015, the success rates range from 37% per embryo transfer leading to a live birth for patients under 30 years, to 8.8% per embryo transfer leading to a live birth for patients over 40 years.
The global infertility devices market was valued at US$ 7,104.1 million in 2018, and is expected to exhibit a CAGR of 8.4% over the forecast period (2019-2027).
Figure 1. Global Infertility Devices Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2019)
Rising adoption of collaboration and acquisition strategies by the market players are expected to boost growth of the infertility devices market
The infertility devices market is expected to witness significant growth, owing to increasing adoption of acquisition, and collaboration strategies by the market players. For instance, in July 2019, Thermo Fisher Scientific Inc. entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group Inc. focused on studying the underlying genetic factors leading to infertility in women. Moreover, in June 2018, Vitrolife AB, and GE Healthcare entered into a partnership to improve its assisted reproductive technology offerings. This partnership has helped Vitrolife to expand its IVF product portfolio in the global market.
Rising age is associated with increasing chances of infertility, which is expected to bolster the infertility devices market growth over the forecast period. According to the National Survey of Family Growth’s factsheet, in 2017 nearly 8.8% of women aged from 15 years to 49 years were infertile among these, around 12.7% of women received infertility services from 2015 to 2017 in the U.S.
Increasing awareness among healthcare professionals about infertility treatment is expected to fuel adoption of such treatment options, which is further expected to propel the market growth over the forecast period. For instance, in 2017, Merck in collaboration with Genea, launched Centre of Excellence for Fertility (CoE) to offer scientific and clinical training modules for fertility professionals, to equip them with advanced understanding to produce enhanced clinical outcomes for patients.
Moreover, increasing product approvals and product launches by the key players are expected to boost growth of the infertility devices market over the forecast period. For instance, in September 2019, FUJIFILM Irvine Scientific, Inc. launched Vit Kit-NX (Vit Kit-NX comprising of Vit Kit Freeze-NX and Vit Kit Warm-NX) as addition to an established portfolio of vitrification solutions for in vitro fertilization (IVF).
Figure 2. Global Infertility Devices Market Share (%), by Product Type, 2019 and 2027
Source: Coherent Market Insights Analysis (2019)
Infertility Devices Market - Regional Analysis
North America is expected to hold a dominant position in the global infertility devices market in 2018, owing to high presence of charitable trusts that provide funds to infertile individuals for treating infertility problems. For instance, BabyQuest Foundation is a charitable organization based in California, U.S., was established in 2011. The goal of this non-profit organization is to grant financial assistance to those who cannot afford infertility treatments such as IUI, IVF, and egg donation. They disburse funds twice a year according to the availability of funds.
Europe is expected to account for significant market share in the global infertility devices market over the forecast period, owing to favorable reimbursement policies for infertility treatment by the government and facility expansion by the market players in the region. For instance, in December 2019, The Cooper Surgical, a subsidiary of the Cooper Companies Inc., opened a new center of excellence IVF training lab in Malov, Denmark to increase its presence in the Europe market.
Moreover, Asia Pacific is expected to witness significant growth in the infertility devices market during the forecast period. The market in the Asia Pacific is expected to gain momentum during the forecast period, owing to an increasing prevalence of infertility rates in the Asian population. For instance, according to the Indian Society of Assisted Reproduction (ISAR) report of 2017, infertility affects around 10 to 14% of the Indian population, with higher rates in urban areas where one out of six couples are affected from it.
Key Players
Major players operating in the global infertility devices market include Carl Zeiss Meditec AG, Thermo Fisher Scientific Inc., Vitrolife AB, The Baker Company, Inc., The Cooper Companies, Inc., Fujifilm Irvine Scientific, IVFTECH APS, Kitazato Corporation, MedGyn Products, Inc., Rocket Medical plc, SOMATEX Medical Technologies GmbH, Cook Group Incorporated, Esco Micro Pte Ltd, Hamilton Thorne, Ltd, and Art Biotech Pvt. LTD.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]
OSTEOARTHRITIS DRUGS MARKET ANALYSIS
Osteoarthritis, also known as degenerative joint disease, is the most common form of arthritis. It can affect various joints in the body. However, the disease has major impact on the knees, neck, lower back, hips, and small joints of fingers.
The global osteoarthritis drugs market size was valued at US$ 5,895.1 million in 2017 and is expected to exhibit a CAGR of 8.2 % over the forecast period (2018 – 2026).
Figure 1. Global Osteoarthritis Drugs Market Value (US$ Mn), by Region, 2017
Source: Coherent Market Insights Analysis (2019)
Increasing incidences of rheumatoid arthritis is expected to propel growth of the osteoarthritis drugs market
Osteoarthritis is caused due to injury, obesity, and several other factors. It leads to severe joint pain and stiffness of the affected body part. The symptoms of osteoarthritis are swelling in joints, numbness in legs and arms, and decreased range of motion. High prevalence of rheumatoid arthritis is expected to drive the market growth. According to the Rheumatoid Arthritis. Org Facts, October 2018, around 1.3 million people in the U.S. and around 1% of world population is affected by rheumatoid arthritis, which is the third major form of osteoarthritis and gout.
Moreover, increasing prevalence of obesity associated with deskbound lifestyle is expected to propel growth of the osteoarthritis drugs market over the forecast period. Obesity causes additional pressure on knees and hips, which in turn can affect the cushion joints to breakdown faster. According to the World Health Organization (WHO) factsheet February 2018, around 1.9 billion adults aged above 18 years were overweight, worldwide in 2016, of which around 650 million were obese.
However, availability of only symptomatic treatment rather than permanent cure of osteoarthritis is the major factor that is expected to hinder the market growth. Harmful effects of regular administration of nonsteroidal anti-inflammatory drugs (NSAID) in osteoarthritis treatment can cause cardiovascular events such as heart attack and stroke, which is further expected to restrain the market growth.
Figure 2. Global Osteoarthritis Drugs Market Share (%), by Route of Administration,
Source: Coherent Market Insights Analysis (2019)
Increasing geriatric population in North America is expected to bolster the market growth
North America holds dominant position in the global osteoarthritis drugs market, owing to increasing geriatric population that is prone to high risk of osteoarthritis. According to the Centers for Disease Control and Prevention (CDC) factsheet 2018, around 29.3% and 49.6% population aged 45 to 64 and above 65 years, respectively were diagnosed with arthritis from 2013 to 2015 in the U.S. Similarly, according to the National Centre for Biotechnology Information (NCBI), December 2016, around 14 million individuals were diagnosed with symptomatic knee osteoarthritis and around 2 million people below 45 years of age were diagnosed with symptomatic knee osteoarthritis, where 6 million cases were diagnosed in people aged 45 to 64 years and above 65 years in the U.S.
Moreover, increasing institutional initiatives to collaborate with key players for research regarding osteoarthritis is expected to drive the market growth. For instance, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), in collaboration with GlaxoSmithKline, Merck Sharp & Dohme Corp., Novartis, and Pfizer, initiated a nationwide research study known as Osteoarthritis Initiative: A Knee Health Study, to examine people with knee osteoarthritis or those prone to knee osteoarthritis.
Moreover, key players in the market are focused on receiving approvals for novel products that aid in treatment of osteoarthritis. For instance, in May 2018, Eli Lilly and Company received U.S. Food and Drug Administration (FDA) approval for Olumiant (baricitinib), a Janus kinase (JAK) inhibitor used in treatment of moderate to severe rheumatoid arthritis that has low response towards tumor necrosis factor inhibitor.
Key Players
Major players operating in the global osteoarthritis drugs market include Pfizer Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Pharma plc., Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Inc., Sanofi, Flexion Therapeutics, Inc., Regeneron, and GlaxoSmithKline Plc.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]